Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.
The combination of apatinib and gefitinib demonstrated the feasibility of dual VEGFR/EGFR inhibition in patients with advanced EGFR-mutant non–small cell lung cancer, according to progression-free survival results of the phase 3 ACTIVE trial that were reported at the ESMO Virtual Congress 2020.
Positive safety, pharmacokinetic, and pharmacodynamic data were reported for the first-in-human phase 1 dose-escalation trial of MGD019 during the European Society for Medical Oncology Virtual Congress 2020 as well as preliminary antitumor activity in select tumor types.
Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.
Patients with completely resected stage IIIAN2 non–small cell lung cancer should not be recommended for post-operative radiotherapy, according to results from the phase 3 LungART trial that were presented during the ESMO Virtual Congress 2020, due to nonstatistically significant increase in disease-free survival versus those treated in the control group.
Findings from the phase 3 monarchE trial reported at the ESMO Virtual Congress 2020 showed that the risk of invasive disease with abemaciclib plus endocrine therapy was significantly reduced versus endocrine therapy alone in patients with high-risk early hormone receptor-positive, HER2-negative breast cancer.
Petros Grivas, MD, PhD, discusses the challenge with biomarker discovery currently in the treatment landscape of urothelial carcinoma.
The pathologic complete responses were significantly improved with neoadjuvant atezolizumab in combination with nab-paclitaxel plus doxorubicin and cyclophosphamide compared with placebo and chemotherapyin patients with stage 2 or stage 3 triple-negative breast cancer.
Patients with HR-positive, HER2-negative breast cancer experienced significant benefit when treated with neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide.
Patient-reported outcomes data showed the quality of life was not reduced with niraparib in patients with ovarian, primary peritoneal, or fallopian tube cancer compared with placebo.
A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Abemaciclib in combination with tamoxifen led to an improvement in overall survival compared with abemaciclib alone in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Notably, the benefit of the combination was observed across all subgroups in the study, according to findings from the final OS analysis of the nextMONARCH trial presented during the 2020 European Society of Medical Oncology Virtual Congress.
According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
In the phase 1 GARNET trial, durable antitumor activity was observed with dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer. The disease control rate was promising and the safety profile of the agent was tolerable, according to results presented during the 2020 European Society of Medical Oncology Virtual Congress.
Final results from cohort 1 of the phase 3 TROPHY-U-01 trial reported continued significant activity with sacituzumab govitecan-hziy as treatment of patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.
The phase 3 COMBI-I clinical trial of spartalizumab plus dabrafenib and trametinib showed no improvement in investigator-assessed progression-free survival in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, missing the primary end point in part 3 of the study.
For patients with advanced gastrointestinal stromal tumors, there was continued clinically meaningful benefit with the novel broad-spectrum KIT and PDGFRα inhibitor ripretinib in the fourth line or later, according to updated data from the randomized phase 3 INVICTUS trial presented at the 2020 ESMO Virtual Congress.
The primary end point of investigator-assessed progression-free survival was missed in part 3 of the randomized, Phase 3 COMBI-i study of spartalizumab in combination with dabrafenib and trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, according to results presented at the 2020 ESMO Virtual Congress.
The use of encorafenib and binimetinib followed by immunotherapy demonstrated a higher progression-free survival, as well as an objective response rate and median PFS at 1 and 2 years that were consistent with those reported in pivotal studies, according to a presentation by Paolo Ascierto, MD, at the 2020 ESMO Virtual Congress.
Postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer in the SOLAR-1 trial experienced prolonged overall survival with alpelisib and fulvestrant even though the study did not cross the prespecified O’Brien-Fleming efficacy boundary (P ≤ .0161), according to research presented at the 2020 ESMO Virtual Congress.
The co-primary end points of overall survival in patients with metastatic urothelial cancer were not met in the phase 3 DANUBE trial of durvalumab in combination with tremelimumab and durvalumab monotherapy, according to results presented at the 2020 ESMO Virtual Congress.
The health-related quality of life had clinically meaningful improvements with pembrolizumab as a first-line therapy for patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer versus standard-of-care chemotherapy, according to new data presented at the ESMO Virtual Congress 2020.
At 4 years of follow-up, nivolumab and ipilimumab in combination as first-line therapy of advanced renal cell carcinoma demonstrated durable benefit versus sunitinib, according to research presented at the 2020 ESMO Virtual Congress.
For patients with progressive pancreatic or midgut neuroendocrine tumors, improvements in disease-free survival and progression-free survival were seen when the dosing of lanreotide Autogel was increased from 120 mg every 28 days to every 14 days. Data from the phase 2 CLARINET FORTE study suggest that this treatment option can delay switching to a more toxic treatment, which was presented at the 2020 ESMO Virtual Congress.
A first-in-human study of the bispecific antibody RO7122290 alone or in combination with atezolizumab showed preliminary antitumor activity and a good safety profile for patients with advanced solid tumors, according to findings of the trial presented at the ESMO Virtual Congress 2020.
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.
The combination of atezolizumab, carboplatin, and nab-paclitaxel increased pathological complete response by 10% or more in “immune-rich” patients with high-risk and locally advanced triple-negative breast cancer, as well as turned PD-L1 negative tumors positive most patients treated with immunotherapy, according to the phase 3 NeoTRIPaPDL1 trial data presented at the 2020 ESMO Virtual Congress.
The addition og xevinapant to standard cisplatin-based concomitant fractionation chemoradiation therapy led to a reduction in the risk of mortality as treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Frontline nivolumab in combination with cabozantinib demonstrated a 49% reduction in the risk of disease progression or death as treatment of patients with advanced renal cell carcinoma.
The use of durvalumab as treatment of patients with resectable non–small cell lung cancer in the neoadjuvant setting showed preliminary promise with a satisfactory complete surgical resection rate, according to the phase 2 IFCT-1601 IONESC study.